The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C.

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...

Type 1 diabetes concept suggested by insulin syringe] adrian825 Vertex Pharmaceuticals (NASDAQ:VRTX [ has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental therapy for ...

Popular themes on Wall Street today include artificial intelligence (AI), the market for weight management medicines, and the ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

Chronic low back pain (CLBP) is a widespread and long-lasting condition defined by lower back pain that lasts for at least 12 weeks. The l ...

The pain management drug market is expected to reach about $125 billion less than 10 years from now, according to Precedence Research. And considering the lack of options, as mentioned, Vertex's ...

The opioid crisis has made it even more urgent to come up with novel approaches to treating suffering. Finally there’s ...